Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021
Conference Call and Webcast Scheduled for 8:45 a.m. Eastern Time Tomorrow

SALT LAKE CITYSept. 23, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast tomorrow, September 24, 2014 at 8:45 a.m. Eastern time to discuss top-line results from its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study ( The Company plans to issue a press release detailing top-line results tomorrow prior to the conference call.

Conference call details:
Date: September 24, 2014 
Time: 8:45 a.m. US Eastern time 
Dial-in number: 1 (877) 407-9708
Replay details: 
Dates: September 24, 2014 until December 31, 2014 
Dial-in number: 1 (877) 660-6853 / 1 (201) 612-7415 
Conference ID: 13591771
Webcast details (live broadcast): 

A replay of the webcast will be available at the Company's web site,, in the "Investor Relations" section.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's lead product candidate, LPCN 1021, is currently in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth.

Forward-Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and includes statements that are not historical facts relating to expectations regarding clinical trials, the potential uses and benefits of Lipocine's product candidates, and Lipocine's product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to (i) the receipt of regulatory approvals, (ii) the results of clinical trials, (iii) patient acceptance of Lipocine's products, (iv) the manufacturing and commercialization of Lipocine's products, and (v) other risks detailed in Lipocine's filings with the U.S. Securities and Exchange Commission (the "SEC"), including, without limitation, its Form 10-K and other reports on Form 10-Q and Form 8-K, all of which can be obtained on the Company's website at or on the SEC website at www.sec.govLipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.